Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00560989 · ClinicalTrials.gov registry record
Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis
A clinical trial of Sarcoidosis and Berylliosis, sponsored by National Jewish Health.
- Completed
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT00560989: Completed study of Sarcoidosis and Berylliosis, sponsored by National Jewish Health.
NCT00560989 is a study of Sarcoidosis and Berylliosis that has completed, run by National Jewish Health. The registered enrollment target is 400 participants, below the 2,150-participant average among 21 other Sarcoidosis trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00560989, a study of Sarcoidosis and Berylliosis, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Granulomatous lung diseases are diseases in which inflamed clusters of white cells, known as granulomas, form in lung tissue. Chronic beryllium disease (CBD) and sarcoidosis are two granulomatous diseases that share similar clinical symptoms, physiological changes in the lungs, and immune responses to the disease. Genetic variations may make some people more susceptible to developing CBD or sarcoidosis. This study will identify common genetic regions associated with increased risk of developing the granulomatous diseases CBD and sarcoidosis.
Conditions Studied
Study Locations (1)
Colorado
- National Jewish Medical and Research Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-03 |
What the finished NCT00560989 record still lists
NCT00560989 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 2,150-participant average among 21 other Sarcoidosis trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Sarcoidosis appearing as the primary indexed condition, and to 0 interventions.
NCT00560989 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT00560989 about?
NCT00560989 is a clinical study titled "Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis". Granulomatous lung diseases are diseases in which inflamed clusters of white cells, known as granulomas, form in lung tissue. Chronic beryllium disease (CBD) and sarcoidosis are two granulomatous diseases that share similar clinical symptoms, physiological changes in the lungs, and immune responses ...
What is the current status of trial NCT00560989?
This trial is currently completed. The enrollment target is 400 participants. The study started on 2007-03. Estimated completion is 2007-03.
What conditions does trial NCT00560989 study?
This clinical trial studies the following conditions: Sarcoidosis, Berylliosis.
Who is sponsoring clinical trial NCT00560989?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00560989 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00560989's enrollment target sits among peer trials
400 6th of 21 higher than 16 of 21 other Sarcoidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
RECRUITING
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
Cardiac Sarcoidosis Randomized Trial
RECRUITING · Phase 3
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
-
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
RECRUITING
-
Vitamin D Homeostasis in Sarcoidosis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia